On Jul. 16, 2020, Catalent and Humanigen announced the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab, Humanigenﾒs proprietary Humaneeredﾮanti-human granulocyte macrophage-colony stimulating factor monoclonal antibody.